Women’s Health Market to Register 3.2% CAGR till 2027; Increasing Availability of Female Health Products on Online Pharmacies to Boost the Market

The global women’s health market size is projected to reach USD 41.05 billion by 2027 on account of the rising demand for medicines and solutions for managing menopause-related disorders, shares Fortune Business Insights™ in its report, titled “Women’s Health Market Size, Share & COVID-19 Impact Analysis, By Application (Contraceptives, Osteoporosis, Menopause, Infertility, and Others) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2020-2027”. The report states that the value of the market stood at USD 35.02 billion in 2019 and the market is predicted to grow at a CAGR of 3.2% from 2020 to 2027.

The COVID-19 pandemic has hampered the women’s health market growth as several pharmaceutical companies have been reporting falling sales due to the restrictions imposed by governments. In addition, cancellation or deferral of non-essential surgeries has further impacted the revenues of the key players in this market, resulting in a disrupted growth trajectory of this market.

Bayer and Daré Bioscience Announce License Agreement to Commercialize Ovaprene

Daré Bioscience and Bayer entered into an exclusive agreement in January 2020, which will allow Bayer to commercialize Ovaprene, Daré’s investigational contraceptive product, in the US. Awaiting the US FDA’s clearance, Ovaprene is designed as an investigational hormone-free vaginal contraceptive that needs to be taken on a monthly basis. The product is in clinical development stages, currently being tested to ensure its efficacy in preventing pregnancy. Under the deal, Daré will gain access to Bayer’s trusted clinical and marketing services, but retain control over the development and regulatory processes of Ovaprene.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/women-s-health-market-101847

Concerted Efforts to Promote Women’s Healthcare Awareness to Aid Growth

Women’s healthcare has gained momentum in the past few years across several countries as well as at the international level. Economic analyses have shown that improving women’s health can lead to a substantial rise in national GDPs and benefit the society in general. In many countries, government bodies have been aggressively spreading awareness about health needs of women, formulating progressive policies and schemes to comprehensively tackle this persistent problem. For example, in 2018, the European Union (EU) released a manifesto that vows to improve the health of females by dealing with issues such as equity of opportunities for men and women, promotion of vaccination among women, prevention of diseases at critical junctures in women’s lives, and evaluation policies that have an indirect bearing on healthcare policy. In the US, the Department of Health and Human Services’ observes a National Women’s Health Week in May every year, focusing on reinforcing the importance of women’s health among all members of society. Such concerted efforts are anticipated to favor the growth of this market during the forecast period.

Pharmaceutical Giants to Dominate the Competitive Landscape of the Market

The competitive landscape of this market is monopolized by giants in the pharmaceutical industry such as Bayer and Allergan. These large enterprises, with their strong portfolios, financial robustness, superior research capabilities, and deep distribution networks, are shaping the dynamics of this market. Some of these companies already have well-established business divisions concerning the health of women, while some are entering this space through collaborations and partnerships.

Industry Development:

• October 2019: Amgen and UCB announced the successful marketing authorization to EVENITY by the European Commission. EVENITY has been formulated to treat severe osteoporosis in postmenopausal women, designed to increase bone formation and reduce bone loss, thus lowering the risk of fracture.

List of Key Players Covered in this Market Report:

• AstraZeneca (Cambridge, UK)


• Eli Lilly and Company (Indiana, United States)


• Novartis AG (Basel, Switzerland)


• Pfizer Inc. (New York, United States)


• Agile Therapeutics (New Jersey, USA)


• LUPIN (Mumbai, India)


• Merck & Co., Inc. (New Jersey, United States)


• Amgen Inc. (California, United States)


• Bayer AG (Leverkusen, Germany)

Further Report Findings:

• The contraceptives segment led the market with a share of 34.2% in 2019 owing to the rapidly rising prevalence of unwanted pregnancies worldwide. In the US market, too, the segment held a commanding share of 34.7% in 2019.


• North America is set to command this market share during the forecast period on account of the dominant presence of large pharmaceutical companies in the US. The market size of the region in 2019 stood at USD 18.00 billion

Table of Segmentation